Daniel A. Hamstra, PhD, MD

 

Daniel Hamstra, PhD, MD, is Assistant Professor in the Department of Radiation Oncology. Dr. Hamstra's clinical interests include bladder cancer, kidney cancer, and prostate cancer. He has a significant interest in improving clinical outcomes and quality of life for patients treated with radiation therapy for prostate cancer. He is the principal investigator on two multi-institutional trials for prostate cancer.

• UMCC 2010-064 A Multi-institutional Phase II Study of Hypofractionated Stereotactic Body Radiation Therapy (SBRT) Using Continuous Real-time Evaluation of Prostate Motion
• UMCC 2011-008 A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

In addition, he is the site investigator for the Prostate Cancer Outcomes and Satisfaction With Treatment Quality Assessment (PROSTQA) which is the largest multi-institutional prospective study of patient reported outcomes for health related quality of life following treatment for localized prostate cancer.

Dr. Hamstra is also a member of the steering committee for genitourinary cancers as part of the radiation therapy oncology group (RTOG) and national radiation chair for a recently approved trial: RTOG 1115: A Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GNRH Agonist and TAK-700.

Through the CHCR he is working with Dr. Angie Faegerlin to develop improved tools to communicate the risks and benefits of androgen deprivation therapy (ADT) in men who have experienced biochemical recurrence following treatment for prostate cancer since recent data has suggested that in this setting men do not usually make the decision about whether or not to initiate ADT based upon clinical risk factors but instead are motivated more by anxiety in regard to their prostate cancer which may not be reflective of their clinical risk.